Neuland Laboratories Ltd Q3 FY2024 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/e1bzj87x4np32nwrsz9zhlpx.pdf

Key Takeaways


Revenue Growth & Business Model Transition

Sucheth Davuluri: "If you were to go back 5 years and look into the future, we believe that the business has transpired largely as expected. We definitely could have done things better. But we believe that the overall hypothesis of the Neuland business model remains firm and validated."

Margin Profile & Profitability

Saharsh Davuluri: "See, I think assurance is a very strong word, so I wouldn't go anywhere near that. I think I would probably just kind of circle back to the commentary that Sucheth and I made."

Biotech Funding: A Contained but Real Risk

Saharsh Davuluri: "I think the important thing is that for a limited period, if this biotech funding crunch continues... I don't think there will be any challenges on our business could be an impact. But for now, we don't see a direct impact."

CDMO Relationship Dynamics

Saharsh Davuluri: "as you get closer to the NDA. And if you have validated the process at your side and your site is registered in the NDA, that perhaps could be construed as really a binding kind of a relationship. And post an NDA, if a big pharma comes in and decides to change the CDMO then perhaps there is maybe some strategic impetus behind it."

Peptides & New Capabilities


Guidance & Commitments

CommitmentSpecificsTimeline
Long-term revenue growthApproximately 20% annual growthNext 4 to 5 years
FY25 growthModest growth with some margin normalization and opex rise due to inflation and investmentsFY25
FY26 and beyond growthQuicker growth on the back of existing and new molecules from capacity being created in FY25FY26, FY27 and beyond
Molecule commercializationContinue to commercialize moleculesNext 1 to 3 years
Peptide DMF filingFile one DMF this calendar year, maybe 2 in FY26Calendar year 2024 and FY26
CapexINR100-120 crores broadly, including new block and land acquisitionNext couple of years
Real estate exitExit from joint development, depending on market conditionsHope this calendar year

Key Metrics

MetricQ3 FY24
Total income₹394.9 cr, +46% YoY
EBITDA₹122.7 cr, margin of 31.1%, an increase of 10.8% over Q3 FY23
Profit after tax₹80.7 cr, vs ₹30.4 cr in Q3 FY23
EPS₹62.9 per share
Free cash flow (9M FY24)₹129 cr
Debt positionnegative ₹44.6 cr, debt reduced by ₹38.8 cr
Working capital cycle118 days, improved from 137 days at end of December '23
CAPEX (9M FY24)₹68.2 cr
Unit 3 utilization~57%
Asset turn3 to 3.1, management considers this optimized
Direct exports share76% of revenue
S&P ESG rating64
Revenue growth outlook~20% annually over next 4 to 5 years, management outlook, not formal guidance
FY25 growth outlookmodest growth with some normalization of margins, management outlook
Normal capex expectation₹100 cr to ₹120 cr annually over next couple of years